tetano
Editor, Senior Moderator
Pediatr Infect Dis J
. 2024 Jan 18.
doi: 10.1097/INF.0000000000004193. Online ahead of print. Risk Factors for Severe and Critical Coronavirus Disease 2019 in Children
Kyung-Shin Lee[SUP] 1 [/SUP], Ye Kyung Kim[SUP] 2 [/SUP], Youn Young Choi[SUP] 1 3 [/SUP], Young June Choe[SUP] 4 [/SUP], Myoung-Hee Kim[SUP] 5 [/SUP], Hyunju Lee[SUP] 6 7 [/SUP]
Affiliations
Background: Coronavirus disease 2019 (COVID-19) is generally mild in children; however, severe or critical cases may occur. In this nationwide study, we analyzed clinical manifestations in children diagnosed with severe acute respiratory syndrome coronavirus 2 to identify high-risk groups for severe or critical disease and compared the clinical features between the Delta- and Omicron-dominant periods.
Methods: Data were retrieved from the National Health Insurance Service (NHIS) database and merged with the Korea Disease Control and Prevention Agency-COVID-19-NHIS cohort, which includes information on COVID-19 cases and vaccination records. We included individuals aged <20 years diagnosed with COVID-19 during both periods (Delta: July 25, 2021-January 15, 2022; Omicron: January 16, 2022-March 31, 2022).
Results: Proportion of severe or critical cases was higher during the Delta period than during the Omicron period. The Omicron period saw increased hospitalization for pneumonia and croup and increased likelihood of hospitalization for neurological manifestations. The risk of severe COVID-19 depended on age group (Delta: highest for 12-19 years; Omicron: 0-4 years). This risk was high in children with multiple complex chronic conditions during both periods and with obesity or asthma during the Delta but not during the Omicron period. Two-dose COVID-19 vaccination provided strong protection against severe disease in the Delta period (adjusted odds ratio: 0.20), with reduced effectiveness in the Omicron period (adjusted odds ratio: 0.91). However, it significantly reduced the risk of critical illness (adjusted odds ratio: 0.14).
Conclusions: These findings can facilitate identification of children at high risk of severe or critical COVID-19, who may require intensive medical support, and development of vaccination policies.
. 2024 Jan 18.
doi: 10.1097/INF.0000000000004193. Online ahead of print. Risk Factors for Severe and Critical Coronavirus Disease 2019 in Children
Kyung-Shin Lee[SUP] 1 [/SUP], Ye Kyung Kim[SUP] 2 [/SUP], Youn Young Choi[SUP] 1 3 [/SUP], Young June Choe[SUP] 4 [/SUP], Myoung-Hee Kim[SUP] 5 [/SUP], Hyunju Lee[SUP] 6 7 [/SUP]
Affiliations
- PMID: 38241652
- DOI: 10.1097/INF.0000000000004193
Background: Coronavirus disease 2019 (COVID-19) is generally mild in children; however, severe or critical cases may occur. In this nationwide study, we analyzed clinical manifestations in children diagnosed with severe acute respiratory syndrome coronavirus 2 to identify high-risk groups for severe or critical disease and compared the clinical features between the Delta- and Omicron-dominant periods.
Methods: Data were retrieved from the National Health Insurance Service (NHIS) database and merged with the Korea Disease Control and Prevention Agency-COVID-19-NHIS cohort, which includes information on COVID-19 cases and vaccination records. We included individuals aged <20 years diagnosed with COVID-19 during both periods (Delta: July 25, 2021-January 15, 2022; Omicron: January 16, 2022-March 31, 2022).
Results: Proportion of severe or critical cases was higher during the Delta period than during the Omicron period. The Omicron period saw increased hospitalization for pneumonia and croup and increased likelihood of hospitalization for neurological manifestations. The risk of severe COVID-19 depended on age group (Delta: highest for 12-19 years; Omicron: 0-4 years). This risk was high in children with multiple complex chronic conditions during both periods and with obesity or asthma during the Delta but not during the Omicron period. Two-dose COVID-19 vaccination provided strong protection against severe disease in the Delta period (adjusted odds ratio: 0.20), with reduced effectiveness in the Omicron period (adjusted odds ratio: 0.91). However, it significantly reduced the risk of critical illness (adjusted odds ratio: 0.14).
Conclusions: These findings can facilitate identification of children at high risk of severe or critical COVID-19, who may require intensive medical support, and development of vaccination policies.